We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Chitosan Iron(III) Reduces Phosphorus Levels in Alloxan Diabetes-Induced Rats with Signs of Renal Failure Development.
- Authors
Schöninger, Lisiane M. R.; Dall'Oglio, Rafaela C.; Sandri, Silvana; Rodrigues, Clóvis A.; Bürger, Cristiani
- Abstract
This study evaluates the effect of complex cross-linked chitosan iron-(III) (CH-FeCL) polymer as phosphate binder in renal failure induced by alloxan (150 mg/kg, i.p.) in rats. The animals (male and female) were divided into four groups and received the treatment once a day for 15 days: (i) control group, which received a single injection of saline (3 ml/kg, i.p.) and normal diet; (ii) alloxan group, which received only a dose of alloxan and normal diet; (iii) phosphate (PO4) group, which received diet supplemented with phosphate 1.2%; and (iv) CH-FeCL group, which received diet supplemented with phosphate 1.2% + CH-FeCL 0.5% (0.054% Fe elemental). It was observed that the CH-FeCL treatment did not alter body-weight, relative weight of the organs and haematological parameters in the treated and control groups for both sexes. However, a decrease in serum phosphorus level of the CH-FeCL group was observed after 15 days, compared with the phosphate group in both sexes. The serum iron concentration of the CH-FeCL group did not differ from the control group in either sex. CH-FeCL polymer decreases intestinal phosphate absorption in rats with renal failure and is promising for the treatment of phosphate retention in patients with renal failure.
- Subjects
ACUTE kidney failure; ALLOXAN; CHITOSAN; PATIENTS; THERAPEUTICS
- Publication
Basic & Clinical Pharmacology & Toxicology, 2010, Vol 106, Issue 6, p467
- ISSN
1742-7835
- Publication type
Article
- DOI
10.1111/j.1742-7843.2009.00527.x